Cumberland Pharmaceuticals Inc. (CPIX) Cash Flow Statement
Where CPIX’s cash came from and went, 2025
December 31, 2025 · U.S. dollars- Cash from operations
- $4.9M
- Capital expenditures
- $97,902 0.2% of revenue
- Free cash flow
- $4.8M 10.9% margin
- Returned to shareholders
- $263,478 5% of free cash flow
- Change in cash
- −$6.5M cash at year-end $11.4M
Drawn to scale: where the cash came from and how it was used. Hover for values.
CPIX operating cash flow, capex and free cash flow
CPIX cash flow trends, 2016–2025
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Operating cash flow | $569,4782016 | $4.9M2025 | +27.1%/yr | |
| Capital expenditures | $2.1M2016 | $97,9022025 | −29.0%/yr | |
| Free cash flow | −$1.6M2016 | $4.8M2025 | — | |
| Free cash flow margin | −4.7%2016 | 10.9%2025 | +15.6 pts | |
| Stock-based compensation | $852,1022016 | $408,3202025 | −7.8%/yr | |
| Dividends paid | $02016 | $135,4052020 | — | |
| Share buybacks (net) | $2.5M2016 | $263,4782025 | −22.2%/yr | |
| Capex / revenue | 6.5%2016 | 0.2%2025 | −6.2 pts |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
CPIX cash flow by activity
CPIX net income vs operating cash flow
Operating cash flow above net income usually means earnings are backed by cash (depreciation and stock-based pay are non-cash expenses).
CPIX cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating activities | ||||||||||
| Net income | −$2.9M | −$6.5M | −$6.3M | −$5.7M | −$3.6M | −$3.4M | −$3.5M | −$7.0M | −$8.0M | −$1.0M |
| Depreciation & amortization | $5.3M | $6.0M | $5.8M | $5.3M | $4.6M | $4.7M | $4.4M | $3.0M | $2.6M | $2.4M |
| Stock-based compensation | $408,320 | $301,895 | $365,040 | $447,503 | $741,867 | $1.0M | $1.5M | $1.4M | $1.5M | $852,102 |
| Change in working capital | $2.2M | $1.3M | $4.6M | $11.0M | $8.2M | $3.5M | −$1.6M | $5.9M | −$784,758 | −$3.3M |
| Other non-cash items | −$59,953 | −$1.8M | $1.6M | −$2.6M | −$3.6M | −$493,917 | $2.3M | −$68,557 | $4.1M | $1.7M |
| Cash from operating activities | $4.9M | −$612,186 | $6.1M | $8.5M | $6.3M | $5.4M | $3.1M | $3.1M | −$557,714 | $569,478 |
| Investing activities | ||||||||||
| Capital expenditures | −$97,902 | −$179,714 | −$453,051 | −$2.1M | −$354,462 | −$2.1M | −$246,202 | −$4.3M | −$1.5M | −$2.1M |
| Investments (net) | −$4.5M | $57,842 | −$1.0M | −$13.7M | −$501,893 | −$1.8M | $8.3M | −$3.4M | $11.0M | −$983,981 |
| Acquisitions & other investing | −$131,403 | $179,714 | $1.4M | $2.1M | $354,462 | $2.1M | −$5.8M | −$20.0M | $0 | $0 |
| Cash from investing activities | −$4.7M | $57,842 | −$105,695 | −$13.7M | −$501,893 | −$1.8M | $2.3M | −$27.7M | $9.5M | −$3.1M |
| Financing activities | ||||||||||
| Dividends paid | — | — | — | — | — | −$135,405 | — | −$56.0M | $0 | $0 |
| Share repurchases & issuance (net) | −$263,478 | −$579,049 | −$740,533 | −$1.1M | −$1.4M | −$1.9M | −$3.5M | −$2.9M | −$3.7M | −$2.5M |
| Net borrowing (repayment) | −$10.0M | $2.5M | −$3.4M | $1.2M | $1.2M | −$3.5M | −$1.6M | $10.2M | $5.7M | $2.4M |
| Shares issued | $5.3M | $0 | $0 | $0 | $0 | $0 | $0 | $200,909 | $0 | $0 |
| Other financing | −$1.7M | −$1.7M | −$3.3M | −$2.2M | −$3.4M | −$1.6M | −$33,108 | $55.6M | −$27,950 | −$1.0M |
| Cash from financing activities | −$6.7M | $196,904 | −$7.4M | −$2.1M | −$3.6M | −$7.1M | −$5.1M | $7.1M | $1.9M | −$1.1M |
| Summary | ||||||||||
| Net change in cash | −$6.5M | −$357,440 | −$1.4M | −$7.3M | $2.3M | −$3.5M | $273,675 | −$17.5M | $10.9M | −$3.7M |
| Cash at end of period | $11.4M | $18.0M | $18.3M | $19.8M | $27.0M | $24.8M | $28.2M | $27.9M | $45.4M | $34.5M |
| Free cash flow | $4.8M | −$791,900 | $5.6M | $6.4M | $6.0M | $3.3M | $2.8M | −$1.2M | −$2.0M | −$1.6M |
| Free cash flow margin | 10.9% | −2.1% | 14.3% | 15.2% | 16.6% | 8.8% | 8.2% | −2.9% | −5.0% | −4.7% |
| Capex / revenue | 0.2% | 0.5% | 1.1% | 4.9% | 1.0% | 5.6% | 0.7% | 10.5% | 3.6% | 6.5% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating activities | ||||||||||||
| Net income | −$4.3M | −$3.3M | −$1.4M | −$1.9M | −$735,207 | $1.2M | −$1.9M | −$1.5M | −$1.1M | −$1.9M | −$6.3M | −$1.1M |
| Depreciation & amortization | −$1.0M | $1.6M | $1.3M | $1.3M | $1.3M | $1.3M | $1.8M | $1.4M | $1.4M | $1.4M | $2.1M | $1.5M |
| Stock-based compensation | $77,866 | $106,842 | $172,160 | $81,262 | $80,686 | $74,212 | $74,812 | $76,371 | $71,958 | $78,754 | $93,894 | $83,112 |
| Change in working capital | $1.5M | $2.0M | −$30,274 | $808,423 | $256,945 | $1.1M | $2.4M | $2.5M | −$1.1M | −$1.4M | $2.2M | $1.5M |
| Other non-cash items | $3.9M | $9,237 | −$37,299 | −$76,447 | −$77,726 | $131,520 | −$475,668 | −$1.9M | −$179,368 | −$355,837 | $3.0M | −$771,648 |
| Cash from operating activities | $168,740 | $387,025 | $3,024 | $187,180 | $843,801 | $3.9M | $1.9M | $475,503 | −$855,660 | −$2.1M | $1.0M | $1.2M |
| Investing activities | ||||||||||||
| Capital expenditures | −$1.8M | −$5 | −$43,841 | −$32,237 | −$26,486 | −$47,630 | −$26,809 | −$40,812 | −$46,804 | −$58,186 | −$86,717 | −$95,073 |
| Investments (net) | — | — | −$3.0M | −$690,837 | $285,864 | −$1.2M | −$26,809 | $189,641 | −$46,804 | −$58,186 | $260,639 | −$95,073 |
| Acquisitions & other investing | −$145,459 | −$61,168 | $0 | $32,237 | $26,486 | $47,630 | $26,809 | $40,812 | $46,804 | $58,186 | $86,717 | $95,073 |
| Cash from investing activities | −$1.9M | −$61,173 | −$3.1M | −$690,837 | $285,864 | −$1.2M | −$26,809 | $189,641 | −$46,804 | −$58,186 | $260,639 | −$95,073 |
| Financing activities | ||||||||||||
| Share repurchases & issuance (net) | −$61,000 | −$61,000 | $263,478 | −$10,439 | −$7,171 | −$245,868 | −$98,383 | −$98,815 | −$134,246 | −$247,605 | −$188,970 | −$201,653 |
| Net borrowing (repayment) | −$5.2M | $0 | $0 | $0 | $0 | −$10.0M | −$815,422 | $0 | — | — | — | — |
| Shares issued | $0 | $0 | $0 | $0 | $0 | $5.3M | $0 | $0 | $0 | $0 | $0 | $0 |
| Other financing | −$85,432 | −$702,300 | −$945,216 | −$376,440 | −$143,626 | −$511,131 | −$464,574 | −$438,021 | −$175,329 | $2.7M | −$1.3M | −$680,943 |
| Cash from financing activities | −$5.4M | −$763,300 | −$681,738 | −$386,879 | −$150,797 | −$5.5M | −$1.4M | −$536,836 | −$309,575 | $2.4M | −$1.5M | −$882,596 |
| Summary | ||||||||||||
| Net change in cash | −$7.1M | −$437,448 | −$3.8M | −$890,536 | $978,868 | −$2.9M | $499,430 | $128,308 | −$1.2M | $226,861 | −$186,341 | $258,879 |
| Cash at end of period | $3.9M | $11.0M | $11.4M | $15.2M | $16.1M | $15.1M | $18.0M | $17.5M | $17.3M | $18.5M | $18.3M | $18.5M |
| Free cash flow | −$1.6M | $387,025 | −$40,817 | $154,943 | $817,315 | $3.9M | $1.9M | $516,315 | −$902,464 | −$2.2M | $953,404 | $1.1M |
| Free cash flow margin | −968.5% | 4.2% | −0.3% | 1.9% | 7.5% | 32.9% | 18.0% | 5.7% | −9.2% | −25.8% | 10.2% | 11.3% |
| Capex / revenue | 1,069.9% | 0.0% | 0.3% | 0.4% | 0.2% | 0.4% | 0.3% | 0.4% | 0.5% | 0.7% | 0.9% | 0.9% |
| Operating cash flow / net income | — | — | — | — | — | 3.12 | — | — | — | — | — | — |
Negative numbers are cash paid out. Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported; data from EODHD.
CPIX cash generation
In fiscal 2025 (ended December 31, 2025), Cumberland Pharmaceuticals generated $4.9 million of cash from operations and spent $0.1 million on capital expenditures, leaving free cash flow of $4.8 million, 10.9% of revenue. It returned $0.3 million to shareholders through dividends ($0) and net share buybacks ($0.3 million). Cash and equivalents fell by $6.5 million over the year.
Related: CPIX income statement, CPIX balance sheet. See the CPIX stock overview for the latest quote and news.
CPIX cash flow FAQ
What is Cumberland Pharmaceuticals's free cash flow?
Cumberland Pharmaceuticals's free cash flow was $4.8 million in fiscal 2025: $4.9 million of operating cash flow minus $0.1 million of capital expenditures It was -$0.8 million a year earlier..
How much cash does Cumberland Pharmaceuticals generate from operations?
Cumberland Pharmaceuticals generated $4.9 million of cash from operating activities in fiscal 2025.
How much does Cumberland Pharmaceuticals spend on capital expenditures?
Cumberland Pharmaceuticals spent $0.1 million on capital expenditures in fiscal 2025, 0.2% of revenue, compared with $0.2 million the year before.
How much stock does Cumberland Pharmaceuticals buy back?
Cumberland Pharmaceuticals spent $0.3 million on net share repurchases in fiscal 2025.